cells, 15, 16 thyroid hormone replacement, and malignancy. 17 Hypercoagulation, sticky red blood cells, high platelet count, and uncleavable fibrinogen 18 also contribute to obliteration of large and small vessels in CTEPH. Thus, CTEPH may serve as a human model disease for venous thrombus nonresolution. CTEPH thrombus classically represents a cast of the pulmonary vascular bed, consisting of endothelium, smooth muscle cells, and fibroblasts. 16, 19 Previous animal studies demonstrated that venous thrombus recanalization may occur <24 hours of thrombus formation, 3 and several of these studies focused on the effect of administration of proangiogenic agents on thrombus resolution. 4, 20, 21 In rats, a single bolus injection of recombinant VEGF protein into newly formed venous thrombi under reduced flow conditions resulted in enhanced recanalization and organization. 21 VEGF naked DNA gene transfer and adenovirus-mediated VEGF gene therapy facilitated thrombus recanalization and resolution in both rats and mice. 22, 23 In another study, the induction of angiogenesis with basic fibroblast growth factor and epithelial neutrophil-activating protein (ENA-78) increased neovascularization, but did not affect experimental thrombus resolution. 20 Thus, controversy remains regarding the role of angiogenesis in venous thrombus resolution.
In this work we hypothesized that (1) angiogenesis plays a key role for thrombus resolution, and that (2) CTEPH may result from a condition of decreased thrombus vascularization leading to thrombus nonresolution. We used an experimental model resembling human deep vein thrombosis in transgenic mice conditionally deficient in kinase insert domain protein receptor (Kdr), the predominant cellular receptor for VEGF in endothelial cells, to prove that thrombus resolution is critically dependent on Kdr. Furthermore, we aimed to study thrombus angiogenesis and vascularization at different stages of thrombosis in CTEPH. We harvested red fresh and white fibrotic CTEPH thrombus material and compared those tissues with parent unthrombosed pulmonary artery and with a spectrum of venous and arterial thrombus samples. Parent, unthrombosed CTEPH pulmonary artery is a small piece of artery obtained from a proximal, apparently disease-free site (see online-only Data Supplement for a full description).
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Characterization of Mice With Endothelial Cell-Specific Deletion of Kdr (Kdr Δend )
Kdr loci and the position of the probe used for Southern blot analysis are shown in Figure 1A . Total DNA was isolated from lungs, kidneys ( Figure 1B, lanes 1 and 2) , livers, and hearts (data not shown) of controls (n=8) and Kdr Δend (n=8; Figure 1B , lanes 3 and 4). Digestion with Spe I resulted in a 4.9-kb fragment for the floxed allele and a 15.3-kb fragment for the CRE-deleted allele (Δ allele; Figure 1B) . 24 The floxed allele contains a diagnostic Spe I site, which is absent in the Δ allele ( Figure 1A) . Although only the floxed allele could be detected in the organs of controls ( Figure 1B , lanes 1 and 2), both the floxed and Δ alleles were discernible in Kdr Δend ( Figure 1B, lanes 3 and 4) . Kdr expression in endothelial cells isolated from lungs, kidneys, and liver of Kdr flox/ flox /Tie-2CreER was significantly decreased after tamoxifen (TX) induction compared with cells from animals that did not receive TX (P<0.05; Figure 1C ).
KDR expression was also examined in Tie-2-expressing monocytes of Kdr Δend and controls (n=8 each). Flow cytometry analyses demonstrated that the proportion of KDR + monocytes of total monocytes and of Tie-2 + monocytes did not differ between Kdr Δend and controls ( Figure 1D ). Only <0.25% monocytes expressed KDR, <0.25% monocytes expressed Tie-2, and <0.1% monocytes coexpressed Tie-2 and KDR ( Figure 1D Figure 1C ). Kdr mRNA expression was 1000 times less in monocytes than in endothelial cells ( Figure 1C ), lending support to the expectation that the Kdr Δend phenotype was primarily endothelial cell-dependent.
Kdr Δend did not display a prothrombotic phenotype, because tail bleeding times did not differ from controls (n=10 each; Figure 1E ). Regarding platelet function, the percentage of total and activated leukocyte/platelet aggregates and the percentage of total and activated monocyte/platelet aggregates were similar in Kdr Δend and controls (n=8 each; Figure 1F ).
Delayed Thrombus Resolution in Kdr Δend
To study thrombus resolution, a murine stagnant flow inferior vena cava (IVC) thrombosis model was used. Thrombosis was induced by partial ligation of IVC in Kdr Δend and controls, and thrombi were harvested 3, 7, 14, and 28 days after surgery (Figure 2A-2H ). We were able to harvest thrombi in 73% of Kdr Δend and in 70% of controls (n=8 or 9 per group and individual time point). Weights, cross-sectional areas, and volumes of thrombi from Kdr Δend were significantly increased at all time points compared with controls ( Figure 2I-2K) . Mean relative thrombus volume changes are illustrated in Figure 2L . Thrombus volumes from Kdr Δend decreased at a slower rate between days 3 and 7 and days 7 and 14 than in control thrombi. Table I in the online-only Data Supplement). By day 28, thrombus microvessel density was similar to controls. To verify immunohistochemical findings, the expression of angiogenic markers vascular endothelial cadherin (Cdh5), VEGF (Vegfa), and Kdr was analyzed in thrombi by quantitative real-time PCR. In controls, these 3 markers were highly expressed on days 3 and 7, and decreased significantly by days 14 and 28. By contrast, the expression of Cdh5 and Vegfa in Kdr Δend remained low at all time points ( Figure 3F and 3G ). As expected, Kdr expression was very low on days 3, 7, and 14 in Kdr Δend ( Figure 3H ).
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Diminished Thrombus Macrophage Numbers in Kdr Δend
By day 7, control thrombi had higher counts of macrophages (expressed as a percentage of F4/80-positive cells of total cells per thrombus area) than Kdr Δend thrombi. No significant differences in macrophage counts were observed on days 3, 14, and 28 ( Figure 3M ; Table I in the online-only Data Supplement). CD68 mRNA gene expression was equal in thrombi of Kdr Δend and controls at all time points, except for day 7, where control thrombi displayed more CD68 mRNA compared with Kdr Δend thrombi ( Figure 3N ). This was in good agreement with immunohistochemistry findings. In controls, common leukocyte antigen CD45 (Ptprc, protein tyrosine phosphatase receptor type C) was highly expressed on days 3 and 7, and decreased significantly by days 14 and 28. In Kdr Δend thrombi, Ptprc expression remained low on days 3, 7, and 14; however, by day 28, the expression had increased ( Figure 3O ). mRNA levels of connective tissue growth factor (Ctgf), a marker for organization and fibrotic transformation, was increased on days 3 and 7 in controls, and decreased by days 14 and 28. In Kdr Δend thrombi, Ctgf expression was low on days 3, 7, and 14; however, by day 28, the expression had increased ( Figure 3P ).
Patients
Consecutive CTEPH patients were consented for tissue analyses at the General Hospital of Vienna and the Kerckhoff Clinic in Bad Nauheim. Mean age of CTEPH patients was 58±12 years; 46% were women; and general characteristics matched those of a typical European CTEPH population (Table) . Patients from whom venous and arterial thrombi, acute coronary thrombi, and carotid endarterectomy specimens had been harvested were sex-and age-matched with CTEPH patients (n=46).
Low Expression of Angiogenic Factors in CTEPH Thrombi
By histology, mouse IVC thrombi were similar to human CTEPH thrombi ( Figure 4A-4D ). Von Willebrand factor and platelet endothelial cell adhesion molecule-1 (PECAM1)-positive cell counts were lower in white and red CTEPH thrombi than in parent unthrombosed pulmonary arteries ( Figure 4F-4L ). Gene expression levels of angiopoietin-2 (ANGPT2), PECAM1, CDH5, KDR, podoplanin (PDPN), Tie-2 (TEK), and VEGFA were decreased in white CTEPH thrombi compared with respective parent unthrombosed pulmonary arteries as reference standards ( Figure 5A ). Furthermore, the expression of factors involved in proliferative pathways of vascular cells, such as bone morphogenetic protein receptor type 2 (BMPR2) or transforming growth factor-β1 (TGFβ1, TGFB1), was decreased. By contrast, the thrombogenic molecule plasminogen activator inhibitor-1 (PAI1, SERPINE1) was increased in white CTEPH thrombi ( Figure 5A ). There was no difference in gene expression of CTGF and leukocyte-specific genes (PTPRC, CD68, and MPO) between white CTEPH thrombi and parent unthrombosed pulmonary arteries. When other vascular thrombi (acute femoral thrombi, coronary aspirates, organizing aortic thrombi, carotid thrombendarterectomies, acute pulmonary emboli, subacute, and organizing deep vein thrombi) were analyzed, white CTEPH thrombi displayed more vessel-specific gene expression than in any acute thrombi, but significantly less than any organizing thrombi ( Figure 5B and 5C).
Low Ratio of Angiogenesis Gene Expression/ CTGF Expression in White CTEPH Thrombi
Figure 5B and 5C displays angiogenesis gene expression levels in arterial and venous thrombi at different stages of organization, in comparison with white CTEPH thrombi. CTGF expression levels were rising in venous thrombi in the following order: in vitro clots from CTEPH patients, acute pulmonary emboli, subacute deep vein thrombi, and organizing venous thrombi occluding deep vein segments that were harvested during variceal surgeries. In arterial thrombi, CTGF gene expression levels were increasing in the following order: acute femoral thrombi, coronary aspirates from acute myocardial infarction, and organizing thrombi from aortic aneurysms. In comparator thrombus tissues, but not in white CTEPH thrombi, gene expressions of CDH5, KDR, and PDPN were increasing with increasing CTGF levels. Ratios of CDH5/CTGF, KDR/CTGF, and PDPN/CTGF expression were lowest in white CTEPH thrombi. Respective gene expressions in red CTEPH thrombi were similar to acute arterial and venous thrombi.
Angiogenic Inhibitory Activity of Red CTEPH Thrombus
After 2-dimensional gel electrophoresis of extracts of representative fresh red and organized white CTEPH thrombi ( Figure 4E ), as well as of pulmonary artery tissue from the same patient ( Figure I in the online-only Data Supplement), protein fingerprinting revealed significant differences in protein profiles from these 3 tissues. Organized CTEPH thrombi demonstrated the least variety of protein bands ( Figure IB in the online-only Data Supplement). To find out whether these lysates contain cell stimulatory factors, a BrdU assay was used to analyze DNA synthesis rates of human umbilical vein endothelial cells (HUVECs). Here, stimulation for 24 hours with lysates of fresh red and white CTEPH thrombus material, as well as from parent pulmonary artery tissue in the absence or presence of VEGF, was assessed, while DNA synthesis rates with basal medium served as control. Material from white CTEPH thrombi and CTEPH pulmonary artery tissue was found to stimulate DNA synthesis in HUVEC in a dose-dependent manner >24 hours ( Figure 6A ), similar to lysates from healthy pulmonary artery tissue (data not shown). Heat-induced denaturation of proteins in these lysates reversed their stimulatory effect (data not shown), indicating that thrombus-bound proteins were responsible for the mitogenic activity. The stimulatory activity of lysates at 40 μg/mL was equivalent to VEGF alone at 50 ng/mL, and both, lysates together with VEGF, exhibited an additive effect on DNA synthesis rates in HUVECs. By contrast, red CTEPH thrombi did not influence DNA synthesis in HUVECs.
In an in vitro 3-dimensional angiogenesis assay, isolated tissue lysates did not induce sprout formation, whereas red thrombus material at 40 μg/mL inhibited VEGF-induced sprouting by ≈15% ( Figure 6B ). Material from white CTEPH thrombi, as well as from unthrombosed pulmonary artery tissue, did not affect VEGF-induced endothelial cell sprouting.
Discussion
Vascular endothelial growth factor receptor-2 (KDR) is a type III transmembrane kinase receptor 25 and a predominant endothelial cell receptor to promote VEGF functions through specific intracellular signaling cascades leading to proliferation, migration, survival, and increased permeability, each of which contributes to the angiogenic response. 26 Endothelial cellspecific deletion of this pathway allowed us to demonstrate the effects of angiogenesis in a model of vascular thrombosis. We were able to confirm the results derived from animal studies in CTEPH, which is a human model disease for thrombus nonresolution.
The Tie-2 receptor is expressed by endothelial cells and hematopoietic stem cells. 27 Transgenic mice expressing inducible CRE recombinase under the control of a Tie2 promoter/ enhancer quantitatively excise loxP-flanked (floxed) genes in endothelial cells. [28] [29] [30] Tie-2-expressing monocytes and macrophages have been shown to regulate revascularization of the ischemic limb. 31 Figure 1C and 1D) . The targeted gene deletion in this model primarily addressed angiogenesis. We found that baseline KDR expression in monocytes was extremely low in our model; values were similarly low as in a previously reported study. 32 Only <0.25% monocytes expressed KDR. Kdr mRNA expression was 1000 times less in monocytes than in endothelial cells ( Figure 1C ). In addition, it has been shown that human monocytes express only vascular endothelial growth factor receptor-1 (Flt-1) and not KDR, whereas endothelial cells express both receptors. 33, 34 In our study, Kdr Δend were used in a stagnant flow venous thrombosis model, 12 where thrombus formation and thrombus resolution are inextricably overlapping. Kdr Δend did not have a prothrombotic phenotype, as tail bleeding times and the percentage of total and activated leukocyte/platelet aggregates and monocyte/platelet aggregates did not differ from controls ( Figure 1E and 1F ), but the lack of Kdr impacted thrombus early on, leading to larger thrombus by days 1 to 3 ( Figure 2I-2K ). Decreased numbers of microvessels in Kdr Δend were primarily apparent during days 7 to 14, whereas vessel density was increasing by day 28 ( Figure 3E ; Table I in the online-only Data Supplement), which may be enhanced by thrombus shrinkage in later stages of this model. Because vascular endothelial cadherin as well as VEGF and Kdr mRNA levels were significantly decreased between ligation and day 7 ( Figure 3F-3H) , we conclude that early compromise of angiogenesis in this model accounts for the difference in thrombus size. This concept is further supported by the analysis of changes in thrombus volumes with the largest difference between days 3 and 7 ( Figure 2L ) and by published data showing that recanalization may occur <24 hours of thrombus formation. 7 Leukocyte recruitment and especially macrophages play a central role in thrombus resolution, and impaired monocyte recruitment delayed thrombus resolution. 35, 36 Monocytes secrete chemoattractants, growth factors, and proteases, 7 thus directing the chemokine/cytokine milieu to resolution. Areas of venous thrombi containing large numbers of monocytes are also rich in neovascular channels. 7 In our model, the expression of CD68 and Ptprc was attenuated during the early phase of thrombus resolution in Kdr Δend (Figure 3N and 3O) . There was no evidence that monocytic Kdr is targeted by the gene deletion, suggesting that angiogenesis may have to occur first to enable monocyte recruitment into resolving thrombi.
A possible intrinsic effect of TX and CRE recombinase on angiogenesis and thrombus resolution was excluded by experiments showing similar thrombus resolution rates in Figure 3H ). TX treatment was terminated 1 week before ligation to minimize toxicity and avoid a direct effect of the compound on venous thrombus resolution. The re-emergence of Kdr expression by day 28 in Kdr Δend may derive from other cells, such as bone marrow-derived endothelial progenitor cells ( Figure 3H ) that invade the late thrombus, and may be enhanced by thrombus shrinkage in later stages of this model. Many other signaling pathways beyond VEGF participate in the formation of new vessels, for example, notch/delta, ephrin/ Eph receptor, roundabout/slit, and netrin/UNC receptor families, as well as intracellular proteins such as hedgehog and sprouty. 37 It is possible that Kdr Δend compensated the loss of Kdr by 1 of these angiogenic signaling pathways, contributing to an increase in microvessels in Kdr Δend by day 28.
After a successful proof-of-concept demonstration that angiogenesis in the animal model is a key component for resolution of experimental thrombosis, angiogenesis was investigated in the vascular obstructive material of CTEPH. CTEPH is a rare and late sequela of venous thromboembolism (VTE), which is characterized by nonresolving thrombi in the pulmonary arteries ( Figure 4E ) and is, therefore, an ideal model disease to study the vascular remodeling of thrombosis.
Parent pulmonary artery is a traditional comparator tissue for CTEPH thrombi because it eliminates patient-to-patient variability. In addition, pulmonary artery is characterized by the same main components, that is, endothelial cells, smooth muscle cells, fibroblasts, and occasional inflammatory cells as CTEPH vascular occlusions. Previously published work by our group has used parent pulmonary artery as control tissue for gene expression studies in CTEPH thrombus. 19 Red appositional CTEPH thrombus corresponds to erythrocyte-rich nonorganized thrombus that is thought to originate from slow flow. In addition, red thrombus composition is characterized by very few vascular resident cells, such as smooth muscle cells and myofibroblasts (Figure 4) , and significantly differs from white thrombus by proteomic analyses ( Figure I in the online-only Data Supplement).
Lower gene expression levels of KDR were found in white CTEPH thrombi compared with pulmonary arteries from the same patients ( Figure 5A ). Not only KDR but also other genes important for endothelial cells (eg, ANGPT2, PECAM1, CDH5, PDPN, TEK, VEGFA, BMPR2, and TGFB1) were expressed at lower levels in CTEPH thrombi compared with pulmonary arteries. Changes in gene expression may reflect different proportions of cell types (especially of endothelial cells) present in CTEPH vascular scars versus relatively normal pulmonary artery walls. Lymphangiogenesis seems to be Figure 6 . Proliferative and sprouting activity of red chronic thromboembolic pulmonary hypertension (CTEPH) thrombus, white CTEPH thrombus, and CTEPH pulmonary artery lysates. A, Activity of protein lysates from CTEPH thrombi and pulmonary arteries was verified by their effect on DNA synthesis rates of human umbilical vein endothelial cells (HUVECs) in a BrdU assay. The DNA synthesis rates after 24 h incubation with different concentrations of homogenized red CTEPH thrombi, white CTEPH thrombi, or CTEPH pulmonary artery tissue (n=3 each) in the absence or presence of 50 ng/mL vascular endothelial growth factor (VEGF; positive control) are demonstrated. Values determined in the absence of any additives to basal medium (BM) were set at 100% (control). B, Inhibitory effects of red CTEPH thrombus on HUVEC sprouting. HUVEC spheroids were stimulated with red CTEPH thrombi, white CTEPH thrombi, or CTEPH pulmonary arteries (n=3 each) in the absence or presence of 25 ng/mL VEGF (positive control) for 48 h. HUVEC spheroids stimulated in the absence of any additives to BM served as controls. Bars illustrate mean total lengths of sprouts. *P<0.05 compared with red CTEPH thrombi, ▼ compared with BM, ▲ compared with VEGF in addition to BM.
Figure 5.
Real-time PCR analyses of white chronic thromboembolic pulmonary hypertension (CTEPH) thrombi, using different vascular tissue comparators (arterial thrombi in B, venous thrombi in C). A, Relative expression of several vessel and leukocyte-specific genes in white CTEPH thrombi compared with unthrombosed pulmonary arteries from the same patients (n=15), with pulmonary artery signals set to 0. B, Relative expressions of CTGF and several vessel-specific genes (CDH5, KDR, PDPN) in in vitro whole blood clots from CTEPH patients (n=6), in acute femoral thrombi (n=4), in coronary aspirates from acute myocardial infarctions (n=7), in organizing thrombi from aortic aneurysms (n=6), in carotid endarterectomies (n=8), and in red CTEPH thrombi (n=8) compared with white CTEPH thrombi (n=15). C, Relative expression of vessel-specific genes as in B in in vitro whole blood clots from CTEPH patients (n=6), in acute pulmonary emboli (n=5), in subacute deep vein thrombi (n=4), in organizing venous thrombi (n=6), and in red CTEPH thrombi (n=8) with white CTEPH thrombi signal set to 0 and normalized to 18S RNA. *P<0.05 compared with white CTEPH thrombi. CTEPH in vitro clots and red CTEPH thrombi are shown in both data sets. more important in arterial thrombosis ( Figure 5 ) and remains to be characterized in the vascular remodeling of venous thrombosis. In accord with reported data, PAI1 showed an increased expression level in CTEPH thrombi 19 ( Figure 5A ). In addition to its role as the main fibrinolysis inhibitor in humans, PAI1 was shown to inhibit cerebral angiogenesis 38 and sprout formation of HUVECs and human lung microvascular endothelial cells. 39 Moreover, pharmacological inhibition of PAI1 promoted angiogenesis in a mouse model of hind limb ischemia. 40 Because CTEPH is a rare disease, we may assume that acute thrombi that were harvested as controls were unlikely not to resolve. Under these assumptions, we performed relative gene expression analyses using CTGF as a marker for fibrotic transformation (ie, thrombus age) and KDR, CDH5, and PDPN as markers for angiogenesis. The relative quantity of CTGF mRNA as a molecular marker of fibrosis has demonstrated a strong correlation with thrombus collagen content. 12 The first observation was that fresh red appositional CTEPH thrombi contained more CTGF than acute pulmonary emboli. In addition, white CTEPH thrombi at the same level of CTGF expression as organizing deep vein thrombi were characterized by significantly reduced angiogenic gene expression. Comparisons of white CTEPH thrombi with vascular thrombi of different origin and age suggested discordant gene expressions, with a lower angiogenic gene/CTGF expression ratio of white CTEPH thrombi.
Despite islands of vessels particularly at the borders of thrombi, 19 CTEPH thrombi were overall less vascularized compared with pulmonary arteries, which was confirmed by decreased vWf and PECAM1-positive cell counts per mm 2 ( Figure 4I ). Our observations are corroborated by recent data showing angiostatic factors, such as platelet factor 4, collagen type I, and interferon-γ-inducible 10 kDa protein, within CTEPH thrombi. 41 Therefore, experiments were designed to understand the biochemical composition of pulmonary vascular thrombus in CTEPH. Thrombus fingerprinting by 2-dimensional gel analysis illustrated that red CTEPH thrombus was significantly different from white organized CTEPH thrombus and thrombus-free CTEPH pulmonary artery ( Figure I in the online-only Data Supplement). DNA synthesis rates of HUVECs in response to incubation with pulmonary endarterectomy material served to illustrate the biological activity of homogenates. When the activity of lysates was tested in an in vitro 3-dimensional angiogenesis assay, red CTEPH thrombi inhibited VEGF-induced HUVEC spheroids sprouting, whereas white clots and pulmonary arteries were neutral ( Figure 6B ). There are 2 explanations: either white CTEPH thrombi and parent unthrombosed pulmonary artery tissue have a stimulatory factor not present in red CTEPH thrombi, or all 3 have a stimulatory factor and red CTEPH thrombi also carry an inhibitory factor. As previously reported, 19 healthy pulmonary artery did not differ from unthrombosed CTEPH pulmonary artery either in a BrdU assay or in an in vitro 3-dimensional angiogenesis assay (data not shown). These results suggest that the paucity of vessels in white CTEPH thrombus may be enhanced by the angiostatic activity of red thrombus.
One of the limitations of the present work is that we have drawn conclusions on thrombus biology in CTEPH, which is a chronic condition that evolves over months to decades after the initiating VTE, based on experimentation in an acute thrombosis model in the mouse. In addition, despite striking histological similarities between mouse and human thrombi ( Figure 4A-4D) , stagnant flow venous thrombosis in the caval vein may not completely replicate pulmonary embolism. Other limitations of the study include the use of tissue lysates in the in vitro experiments and the focus on soluble proteins rather than cellular components of endarterectomy specimens. Comparisons with arterial thrombosis may be biased by a component of atherosclerotic inflammation, which may be distinct from venous thrombosis. Plasmin and matrix metalloproteinase-related mechanisms play important roles in venous thrombus resolution, 42 yet those remain to be studied in Kdr Δend . The results of our study suggest that angiogenesis and an intact angiogenic response during the early phase of thrombus resolution are key mediators of normal thrombus resolution. The analysis of pulmonary endarterectomy specimens illustrates a paucity of vessels and low ratio between thrombus angiogenesis and fibrosis, supporting the hypothesis that deficient angiogenesis is a key biological mechanism of occlusive vascular remodeling after VTE. Clinical conditions that have been found to be associated with CTEPH, for example, splenectomy, infection, or phospholipid antibodies, must be examined for their possible interaction with the angiogenic response during thrombus organization. Insights into these processes might be helpful in tailoring more specific and effective therapies for VTE, preventing CTEPH.
